Is Allogene Therapeutics (ALLO) Outperforming Other Medical Stocks This Year?Zacks Investment Research • 05/22/20
Allogene Therapeutics, Inc. (ALLO) CEO David Chang on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/09/20
Why Earnings Season Could Be Great for Allogene Therapeutics (ALLO)Zacks Investment Research • 05/05/20
Allogene Therapeutics, in Collaboration with Servier, to Present Initial Results from its Phase 1 ALPHA Study of ALLO-501 AlloCAR T™ Therapy in Relapsed/Refractory Non-Hodgkin Lymphoma at the American Society of Clinical OncologyGlobeNewsWire • 04/29/20
Here's Why Momentum Investors Will Love Allogene Therapeutics (ALLO)Zacks Investment Research • 04/16/20
Allogene Therapeutics' (ALLO) CEO David Chang on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 02/27/20
Allogene Therapeutics Reports Fourth Quarter and Full Year 2019 Financial ResultsGlobeNewsWire • 02/27/20
Allogene Therapeutics, Inc. (ALLO) CEO David Chang on Q3 2019 Results - Earnings Call TranscriptSeeking Alpha • 11/05/19
Allogene Therapeutics and Notch Therapeutics Announce Collaboration to Research and Develop Induced Pluripotent Stem Cell (iPSC)-Derived Allogeneic Therapies for Hematologic Cancer IndicationsGlobeNewsWire • 11/05/19
Allogene Therapeutics Enters Research Collaboration Directed at Enhancing Future Cancer ImmunotherapiesGlobeNewsWire • 09/19/19
Allogene Therapeutics, Inc. (ALLO) CEO David Chang on Q2 2019 Results - Earnings Call TranscriptSeeking Alpha • 08/07/19